Shots:
- The first patient has been dosed in the P-II trial assessing IBI302 in patients with active subfoveal or parafoveal choroidal neovascularization secondary to nAMD. The primary objective is to evaluate the efficacy and safety of IBI302
- The two P- I studies of IBI302 (single/multiple-dose escalation) showed improvement in visual acuity with a reduction in retinal thickness, leakage, and total area of neovascularization in terms of efficacy
- Additionally, the ongoing P-II study of the therapy will focus on improving visual acuity and retinal thickness and the effect on macular atrophy and fibrosis
Click here to read full press release/ article | Ref: PRNewswire | Image: BioSpectrum Asia
The post Innovent Reports First Patient Dosing in P-II Trial of IBI302 for Neovascular Age-Related Macular Degeneration first appeared on PharmaShots.
